

UNSW AUSTRALIA

SCHOOL OF MECHANICAL AND  
MANUFACTURING ENGINEERING

**Development of an automated  
magnetic silica bead based  
DNA/RNA Extractor**

**Jarrold Herbert Stilp**  
z3460979

Bachelor of Engineering, Mechatronic Engineering

November 2016

Supervised by Associate Professor Jayantha Katupitiya

# **Development of an automated magnetic silica bead based DNA/RNA Extractor**

**Jarrold Herbert Stilp**

Submitted for the degree of Bachelor of Engineering,

Mechatronic Engineering

November 2016

## **Abstract**

Most of these first few pages are generated by the file header/frontpage.tex

However, this file contains a lot of important (and messy) commands for setting up the document which should rarely need to be changed, so I've moved the abstract to a separate file (header/abstract.tex) using an `\include{}` command.

You could do the same with acknowledgements if you wanted to.

# Certificate of Originality

I, Jarrod Herbert Stilp, hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom I have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis.

I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the projects design and conception in style, presentation and linguistic expression is acknowledged.

Signed .....

Date .....

# Acknowledgements

- First

# Contents

<b>Abstract</b>	<b>ii</b>
<b>Certificate of Originality</b>	<b>iii</b>
<b>Acknowledgements</b>	<b>iv</b>
<b>1 Introduction</b>	<b>1</b>
1.1 Background . . . . .	1
1.1.1 The Extraction Process . . . . .	5
1.2 Aim . . . . .	7
1.3 Scope . . . . .	7
1.4 Methodology . . . . .	7
<b>2 Literature Review</b>	<b>11</b>
<b>3 Methodology</b>	<b>12</b>
<b>4 Results</b>	<b>13</b>
<b>5 Discussion</b>	<b>14</b>
<b>6 Conclusions</b>	<b>15</b>
<b>7 Future Work</b>	<b>16</b>

<b>Contents</b>	<b>vi</b>
<b>A Raw Results</b>	<b>17</b>
<b>References</b>	<b>17</b>

# List of Figures

1.1	High-Plex Platform. . . . .	4
1.2	Extractor deck layout. . . . .	8
1.3	Extraction cassette tubes. . . . .	9
1.4	Short caption for list of figures. . . . .	9
1.5	Abbreviated caption. . . . .	10

# Chapter 1

## Introduction

### 1.1 Background

Needed: -Place in industry -Background of diagnosis -Requirement and fit in company -Existing equipment

Within the healthcare industry, there is a continuous need for fast and reliable diagnostics of pathogens within patients. Identifying the presence of pathogens responsible for disease in a patient allows the appropriate preventive or corrective action to be taken and represents a crucial step in treating or preventing illness. This thesis was conducted for the benefit of and in collaboration with AusDiagnostics Pty Ltd.

Successful diagnostics, within the context of this thesis, can be summarised in three overall stages. Namely these are extraction, amplification and finally analysis. This thesis concerns itself only with extraction. It should be noted that not all pathogen analysis and/or commercial diagnostic processes follow these steps strictly, however the processes and technologies applied by AusDiagnostics follow this procedure. The stages of this procedure may be



summarised as follows:

1. **Extraction** To begin the diagnosis, a clinical sample is obtained from the patient. This sample may consist of cerebrospinal fluid, faecal matter, urine or others, depending on the disease to be diagnosed. These samples contain the target DNA or RNA which will later be analysed to determine the presence of the pathogen and hence disease. They also contain however a number of inhibitors to the process of amplification and analysis. Extraction is the process of removing said inhibitors and retaining only the target DNA or RNA. The result is referred to as a clean sample.
2. **Amplification** Amplification takes the clean sample and by one of many methods increases the overall count of the DNA. This may be with the intention of allowing multiple targets to be detected or to increase the sensitivity of the analysis.
3. **Analysis** Analysis uses one of many available methods to search for the presence of biomarkers within the amplified clean sample. The presence of the biomarker indicates the result of the diagnosis.

AusDiagnostics currently supplies customers with the instruments and chemical products required to complete stages two and three (amplification and analysis) of the diagnosis. This requires customers to purchase extraction equipment from alternative suppliers and represents a significant weakness and loss of profit. Research and development conducted by AusDiagnostics has determined that the optimal approach, when considering speed and efficiency, is super-paramagnetic bead based extraction. The beads utilised are of the shell-core variety. The core is composed of an iron oxide, which provides the super paramagnetic properties required for physical manipulation of the

beads via a magnetic field. The shell is comprised of silica, which via chemical modification has the propensity to bond DNA and RNA to the bead surface. The techniques developed by researchers at AusDiagnostics utilising the magnetic silica beads have been validated and verified via manual operation. This thesis concerns itself with the automation of the developed extraction process, to produce a commercially viable robotic instrument. This instrument will be referred to as the Gene-Plex Extractor.

The extraction process to be automated has a number of notable requirements. These include liquid handling via precise pipetting, including mixing and liquid transfer. Also required is manipulation of the magnetic silica beads to separate the bonded and hence captured target DNA or RNA, along with heating to a specified, constant temperature to act to increase the rate of the chemical processes. The automation of the extraction process will be achieved by integrating the required capabilities into the robot produced by AusDiagnostics to conduct the amplification stage of diagnosis. The instrument, based of the Gene-Plex platform and sold as the High-Plex Processor, is pictured in it's current application in Figure 1.1. The Gene-Plex platform is essentially a liquid handling robot. The robot carries out the amplification stage by precisely pipetting and transferring liquid mixtures between the tubes and instruments on the deck, using disposable tips. Each individual assay (an analysis conducted to determine the presence and amount of a substance within a volume) utilises an individual layout of components on the robots deck. This makes the platform highly configurable for differing setups.



Fig. 1.1: The Gene-Plex liquid handling robot platform, as implemented as the High-Plex Processor.

### 1.1.1 The Extraction Process

In order to allow the aims and scope of the work to be clearly defined, a condensed overview of the extraction process developed by AusDiagnostics is presented. It should be noted that unless explicitly stated, all operations are to be automated.

The extraction process requires that the clinical sample undergoes a number of chemical steps across different locations on the robot. To aid in understanding the liquid handling involved, Figure 1.2 displays the important sites on the deck. The process will begin with the operator manually loading 24 individual clinical samples into the location labelled “Clinical Samples”. In order to conform to existing products used by customers, it is then required that the chemical processing takes place in the locations labelled “Samples”. In order to transfer the liquid between locations, the robot will pick up  $1000\mu\text{L}$  tips from the locations marked “Tips”.

The sample processing locations must accept modules that fit within the standard block size (SBS) format. These blocks are required to each accept 8 cassettes, one for each sample (pictured in Figure 1.3). Each cassette includes 6 tubes, which will be the site of a particular chemical reaction in order to extract the target DNA and RNA:

1.  $500\mu\text{L}$  of clinical sample is pipetted into tube location 2, as marked in Figure 1.3. Within this tube as supplied by AusDiagnostics, there will already be  $10\mu\text{L}$  of magnetic bead mixture along with  $440\mu\text{L}$  of lysis buffer. The lysis buffer will destroy the cell walls, releasing the target DNA or RNA to be bound to the magnetic silica beads. This process is

required to take place at 60degC in order to increase the rate of reaction. Due to the low volume of liquid in this step, it is to be completed in one of the 1mL low profile tubes. This aids with liquid handling precision.

2. The target DNA or RNA is now bound to the beads, which are suspended in the waste liquid (supernatant). In order to capture only the bead suspension, the entire liquid mixture is aspirated via pipette tip and subsequently move to the location marked “Waste Separation”. In this location, a magnetic field is to be applied to capture the magnetic silica beads within the pipette tip. While captured, the supernatant must then be expelled into a waste container in this location. The tip now contains only the magnetic beads with bound targets.
3. Despite the supernatant having been expelled, there will still be a significant amount of waste retained on the bead surface. To remove this and clean the beads, a sequence of 3 wash steps must then occur in tube locations 1, 5 and 6. To achieve this, the beads are first re-suspended in the tube, which contains 800 $\mu$ L of a particular wash buffer. The suspension must then be mixed via pipetting in order to ensure the bead surface is properly exposed. The entire liquid mixture is then aspirated once again and transferred to the waste location, where via the same means as step 2, the waste liquid is disposed of while the beads are retained. This process is repeated 3 times in the tubes noted above to ensure no waste matter clings to the bead surface.
4. With the beads now clean and still bound to the target, the mixture is transferred to location 3 of the cassette. The elution buffer is used to break the bond between the target DNA and RNA and the magnetic silica beads. This process is also required to be completed at 60degC to

reduce the time required. Following this step, the target DNA or RNA of interest is now contained within the elution buffer, along with the magnetic silica beads which are now waste.

5. The final step is to capture only the target DNA or RNA within the elution buffer, leaving behind the magnetic beads. This is required to take place in tube location 4. This is a low volume reaction, containing only  $100\mu\text{L}$  of elution buffer and is therefore completed in the final small profile tube. The pipette must then aspirate this mixture, following bead removal, and contain only the elution buffer and target mixture required for amplification in stage 2 of the assay.

## 1.2 Aim

## 1.3 Scope

## 1.4 Methodology

Figure 1.5 and subfigure 1.5b or b contains ... Table 1.1.

Citations: Luce [?] wrote something important.

Classification	Cost	Description
CLEAR	1	Good for traversing
OBSTACLES	$\infty$	Definitely not traversable
UNKNOWN	4 if distant, $\infty$ if close	Not classified
EXPENSIVE	In range $[2, 50]$	Traversable but should be avoided

Table 1.1: Example table.




Fig. 1.2: The layout to be used for the Gene-Plex Extractor.




Fig. 1.3: The tube format to be used as the site of the sample processing.



Fig. 1.4: Full caption for the Mechatronics Logo. Designed by Wei Hua Chen.





Fig. 1.5: Overall figure caption.

## Chapter 2

### Literature Review

## Chapter 3

### Methodology

## Chapter 4

## Results

## Chapter 5

## Discussion

## Chapter 6

## Conclusions

## Chapter 7

### Future Work

# Appendix A

## Raw Results